iCell Gene Therapeutics receives Orphan Drug Designation for CD5CAR for treatment of T cell leukemia and lymphomas that are positive for CD5.
Read more about it here.
iCell Gene Therapeutics is proud to announce the publication of our preclinical CD5CAR NK cell data in Leukemia, a leading hematology-oncology journal titled "Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor". We demonstrate the efficacy of using CD5-redirected CAR NK cells against various T-cell malignancies and disease subsets expressing CD5. Read more about it here.
iCell Gene Therapeutics is proud to announce the publication of a proof-of-concept article for NK cells. In our article, "Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies", we demonstrate the preclinical efficacy of NK cells directed to the CD3 antigen as a novel approach for targeting T-cell malignancies. Read more about it here.
iCell Gene Therapeutics Receives Orphan Drug Designation for CAR-T Targeting Peripheral T-cell Lymphoma (PTCL)
iCell Gene Therapeutics is proud to announce the publication of our preclinical CD4CAR T-cell data in Leukemia, a leading hematology-oncology journal. In our article, "Preclinical targeting of human T cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells" we demonstrate the efficacy of our CAR technology for the targeting of human CD4 positive T-cell malignancies in blood samples obtained from patients with currently incurable disease. Our study is unique in that it is among the first CAR therapy studies focused on T-cell malignancies, a subset of cancers with poor prognosis and few treatment options for many patients. We are grateful for the opportunity to contribute to the science of CAR therapy, with the long-term goal of enhanced patient outcomes. As a result of our research team’s findings, we are now one step closer to bringing curative CAR therapy to patients with relapsing or resistant T-cell malignancies. Read more about it here.